Evolution of Fentanyl Prescription Patterns and Administration Routes in Salamanca, Spain: A Comprehensive Analysis from 2011 to 2022

Abstract

Introduction: The escalating use of opioids poses a multifaceted challenge, contributing to social, health, and economic crises. In Spain, a notable surge in the medical prescription of opioids in recent years has been observed. In response to this growing concern, the Spanish Agency for the Regulation of Medicines and Healthcare Products issued an alert in 2018 regarding the misuse of opioids. Objective: The aim of this research work was to assess the consumption rate of fentanyl, categorized by the different administration routes, in the province of Salamanca (Spain) spanning the years 2011 to 2022, and also to compare this local trend with the national scenario and with data published in the United States. Material and Methods: Data on fentanyl consumption in the province of Salamanca, measured in defined daily doses (DDD), were sourced from the Regional Health System Registry in Castilla y Leon for each administration route from 2011 to 2022. Doses per inhabitant per day (DHD) were calculated, and interannual variations, as well as consumption rates, were subject to thorough analysis. Results and discussion: The prevalence of fentanyl use in Salamanca has surged from 1.2 DHD in 2011 to 2.56 DHD in 2022, with the transdermal system (TD) as the predominant administration route. This upward trajectory shows a positive correlation, mirroring the national trend, yet the rise in fentanyl usage is markedly lower than the reported data in the US. This finding may be attributed to an ageing population, and potentially inappropriate fentanyl prescriptions, i.e. for the management of chronic non-cancer pain and other off-label prescriptions. Conclusion: The use of fentanyl in Salamanca, particularly through transdermal systems, has doubled from 2011 to 2022, aligning with the national trend. Urgent preventive measures are imperative to prevent fentanyl misuse and moderate the observed escalation in consumption rates.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors received no specific funding for this work

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

留言 (0)

沒有登入
gif